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Cytochrome P450 (CYP) 3A accounts for nearly 30% of the total CYP enzymes in the human liver and 
participates in the metabolism of over 50% of clinical drugs. Moreover, CYP3A plays an important role 
in chemical metabolism, toxicity, and carcinogenicity. New animal models are needed to investigate 
CYP3A functions, especially for drug metabolism. In this report, Cyp3a1/2 double knockout (KO) rats 
were generated by CRISPR-Cas9 technology, and then were characterized for viability and physiological 
status. The Cyp3a1/2 double KO rats were viable and fertile, and had no obvious physiological 
abnormities. Compared with the wild-type (WT) rat, Cyp3a1/2 expression was completely absent in 
the liver of the KO rat. In vitro and in vivo metabolic studies of the CYP3A1/2 substrates indicated 
that CYP3A1/2 was functionally inactive in double KO rats. The Cyp3a1/2 double KO rat model was 
successfully generated and characterized. The Cyp3a1/2 KO rats are a novel rodent animal model that 
will be a powerful tool for the study of the physiological and pharmacological roles of CYP3A, especially 
in drug and chemical metabolism in vivo.
The Cytochrome P450 (CYP) enzymes play an essential role in the biotransformation of endogenous molecules 
and xenobiotics1. Today, almost 75% of drugs on the market are bio-transformed through CYP-mediated metab-
olism and the main CYP isoforms, CYP3A4/5, CYP2C9/19, CYP2D6, CYP1A1/2 and CYP2E1, participate in 
nearly 95% of the reactions2. In particular, CYP3A4, as the most abundant CYP isoform in the human liver and 
intestine, is involved in the phase I transformation of toxins, carcinogens, bile acids, steroid hormones, and more 
than 50% of the drugs used in the clinic3,4. Moreover, CYP3A4 is either induced or inhibited by many chemicals, 
which influences the elimination of co-administrated drugs, leading to therapy failure or unwanted toxicity4,5.
A variety of single CYP enzyme-null mouse models, including Cyp3a, have been reported as potent and pre-
cise tools used to illustrate the potential functions of CYP isoforms on the metabolism, toxicity and carcino-
genicity of chemicals6,7. Until now, however, Cyp3a gene knockout (KO) rats have not been reported due to 
the complexity and limitation of gene editing techniques. Compared with the Cyp3a KO mouse model, Cyp3a 
KO rat model is more important to pharmacological research, especially drug metabolism and pharmacokinetic 
(DMPK) studies. On the one hand, the rat is larger in size, and possesses more blood, compared with the mouse. 
Moreover, rats in some disease models such as breast cancer are physiologically more similar to humans than 
mice8,9. Therefore, the Cyp KO rat model could be a good supplement to the Cyp KO mouse model, overcoming 
some disadvantages of the mouse model. On the other hand, since many CYP isoforms expressed in different 
species possess different substrate affinities, it is very difficult to extrapolate the results from one specific animal 
species to humans4. Therefore, results from multiple animals should be taken into consideration.
Recently, application of the Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/
CRISPR-associated 9 (CRISPR-Cas9) system from Streptococcus pyogenes has greatly reduced the difficulties 
of genome editing in various species including the rat10–12. The CRISPR-Cas9 system consists of a non-specific 
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nuclease, Cas9 protein, and a single guide RNA (sgRNA) that directs Cas9 protein to the target sites using the 
rules of Watson-Crick base-pairing8,11. Compared with previous techniques, the CRISPR-Cas9 system shows 
distinct advantages in editing multiple genes simultaneously10,13. To take advantages of rats in DMPK and disease 
research and to enrich resources of animal model in pharmacology, we want to generate a Cyp3a1 and 3a2 double 
KO rat model via the CRISPR-Cas9 system.
In this study, we successfully created a Cyp3a1/2 double KO rat model using the CRISPR-Cas9 system. 
Cyp3a1/2 double KO rats were characterized for viability and physiological status. The absence of Cyp3a1/2 
expression in rat liver and intestine was confirmed by both PCR analysis of hepatic cDNA and immunohisto-
chemical analysis. Further in vitro and in vivo metabolic studies of the CYP3A1/2 substrates were conducted to 
verify that CYP3A1/2 was functionally inactive in KO rats. The Cyp3a1/2 double KO rat was viable, fertile, physi-
ological normal and presented impaired metabolic ability towards selected CYP3A probe substrates.
Results
Generation of Cyp3a1 and Cyp3a2 double KO rats using CRISPR-Cas9. To investigate the role of 
Cyp3a in drug metabolism, we generated rats with CRISPR-Cas9-mediated disruption in both isoforms of this 
gene. For targeting Cyp3a1, we selected 5′ -CAAGAAACAGGGGATTCC-3′ followed by TGG as the target site, 
and 5′ -TAAGAAACAAGGAATTCC-3′ followed by TGG for targeting Cyp3a2. The targeting strategy is shown in 
Fig. 1. A mixture of Cyp3a1 sgRNA (25 ng/μ L), Cyp3a2 sgRNA (25 ng/μ L) and Cas9 mRNA (50 ng/μ L) was co-mi-
croinjected into one-cell fertilized eggs of Sprague-Dawley (SD) rats and 14 progenies were born. To identify the 
gene modifications of the F0 generation, the targeted loci of Cyp3a1 and Cyp3a2 were PCR amplified and T7E I 
(T7 endonuclease I) cleavages were detected in rat #3, #5, #6 (unexpected death at day 11), #8, #11 and #12 found-
ers for Cyp3a1 and in #3, #5, #7, #9, #12 and #13 founders for Cyp3a2 (Fig. 2a), which indicated the potential for 
genome modification at targeted loci. We sequenced these regions and confirmed these modifications (Fig. 2b,c). 
For Cyp3a1, founders #3, #5, #8 and #11 contained at least one frame-shifting mutation; frame-shift mutations 
were also observed for Cyp3a2 in founders #3, #5, #7, #9 and #13. Thus, founders #3 and #5 were crossed with 
wild-type (WT) rats and the genotypes of F1 offspring were determined. For Cyp3a1, several F1 progeny generated 
from F0-#3, five progeny out of eleven total pups (#3, #4, #7, #8 and #11) showed the same nucleotide deletion 
(deletion of 22 bp) as F0-#3 (Fig. 2d). Nevertheless, the genotype with nucleotide insertion and substitution was 
not transmitted from F0-#3 which may be due to genetic mosaicism caused by the CRISPR/Cas9 system10,14. For 
Cyp3a2, in the F1 generated from F0-#3, again five pups out of eleven (#1, #3, #4, #8 and #11) possessed a 10 bp 
nucleotide deletion (Fig. 2d), which was not even detected in F0-#3. This inconsistency suggested that sequencing 
4 clones of PCR products from F0 tail DNA may be not enough to reveal all genetic modifications14. In conclusion, 
progeny #3, #4, #8 and #11 were identified as Cyp3a1 and Cyp3a2 double KO F1 rats by directly sequencing of the 
PCR products from rat tail DNA. However, in the F1 generation of F0-5#, no Cyp3a1 and Cyp3a2 double KO F1 
rat was obtained (Data not shown). To generate Cyp3a1 and Cyp3a2 double KO and homozygous rats, F1-3#(♀ ) 
was mated with F1-4#(♂ ), and F1-8#(♀ ) was crossed with F1-11#(♂ ) to generate the F2 generation. The genomic 
modification in F1 was transmitted to the F2 generation efficiently and stably with the described mutations in 
Cyp3a1 and Cyp3a2 gene (Fig. 2d).
Off-target analysis. Recent studies have reported that the CRISPR-Cas9 system has a much greater level of 
off-target cleavage than zinc-finger nucleases (ZFNs) and transcription activator-like effector nucleases (TALENs) 
because the target sequence selected by CRISPR-Cas9 can tolerate a 1~3 base pair mismatch8,10,15–17. Hence, we 
examined off-target damage in Cyp3a1 and Cyp3a2 double KO rats. A genome-wide sgRNA off-target searching 
Figure 1. The strategy for generation of the Cyp3a1/2 double knockout rat model. (a) Schematic 
representation of the chromosomal organization of Cyp3a1 and Cyp3a2. (b) Exon/intron structure of Cyp3a1 
and Cyp3a2. Exons are represented as , ‘e’, indicates ‘exon’. (c) Targets selected for the deletion of Cyp3a1 and 
Cyp3a2. (d) Resulting deletions in the animal model.
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Figure 2. Genotyping of Cyp3a1/2 double KO rats generated by the CRISPR-Cas9 system. (a) Detection of 
the mutations in the F0 generation for Cyp3a1/2 by T7E I digestion using PCR products amplified from F0 rats 
tail genomic DNA by Primer No. 1 and 2 (Table 3). T7E I− , before T7E I digestion. T7E I+ , after T7E I 
digestion. , mutant band. DNA sequencing of (b) Cyp3a1 or (c) Cyp3a2 genomic loci in F0 rats. Four TA 
clones of the PCR products amplified from each F0 rat were sequenced. “. ”, nucleotide deletion. Lowercase letter, 
nucleotide insertion. , Red box, nucleotide substitution. “▵ ”, the number of changed nucleotide. “X”, the 
number of each genotype in four clones. (d) The details of mutations in F2 generation.
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tool (COD) was used to pick out off-target sites (OTS) with high potential for mutation by our targeting system. 
OTS with a score of no less than 0.5 was chosen for further analysis. We examined eight and five OTSs for Cyp3a1 
and Cyp3a2 sgRNAs, respectively (Table 1). None of these potential OTSs was mutated in our double KO rats 
(Fig. 3), thus suggesting CRISPR-Cas9 is a reliable gene targeting tool in generating the Cyp3a1/2 double KO rat 
model.
Physiological phenotype of Cyp3a1 and Cyp3a2 double KO rat and WT rat. CYP3A1 and CYP3A2 
enzymes were involved in the metabolism of xenobiotics, steroid bile acids and other compounds. Therefore, the 
deletion of Cyp3a1 and Cyp3a2 may lead to important physiological changes. To investigate the effects of Cyp3a1 
and Cyp3a2 disruption on rat physiology, serum samples were collected at 8 weeks and analyzed for high-density 
lipoproteins-cholesterol (HDL-CHOL), low-density lipoproteins-cholesterol (LDL-CHOL), total cholesterol 
(T-CHOL), triglycerides (TRIG), aspartate amino transferase (AST), alanine amino transferase (ALT), AST/ALT, 
alkaline phosphatase (AP), albumin (ALB), globulin (GLB), ALB/GLB, total proteins (TP), ID-BIL (indirect bili-
rubin), direct bilirubin (D-BIL), total bilirubin (T-BIL), glucose (GLUC), prostaglandin E2 (PGE2), 25-OH vita-
min D, testosterone and bile acid. None of the serum clinical chemistry and physiological indices showed obvious 
abnormalities except for testosterone (Fig. 4a). The concentration of testosterone (a typical substrate of CYP3A) 
increased by 110% in the serum of KO rats. Compared with WT, homozygous Cyp3a1 and Cyp3a2 double KO 
rats seemed to be normal and fertile, with regular liver weight, body weight as well as organ coefficients for both 
genders (Fig. 4a). Furthermore, histological analysis revealed that there were no morphological changes between 
the WT and KO rat liver and small intestine (Fig. 4b). In general, the absence of Cyp3a1 and Cyp3a2 may not 
cause any consequential abnormalities.
Double KO rats lack expression of CYP3A1 and CYP3A2. The expression of CYP3A1 and CYP3A2 
in mRNA levels in double KO and WT rat liver was checked via the specific primer pairs targeting Cyp3a1 and 
Cyp3a2. Our data showed that the mRNA expression of Cyp3a1 and Cyp3a2 was completely absent in double KO 
rat livers (Fig. 5a). We also found no CYP3A1 or 3A2 expression by immunohistology in liver and small intestine 
of double KO rats (Fig. 5b). These results confirmed that the expression of CYP3A1 and CYP3A2 was lost in the 
double KO rat liver and intestine.
CYP3A-mediated metabolism and pharmacokinetics studies in Cyp3a1/2 double KO rats. To 
assess whether CYP3A1/2 was functionally inactive in KO rats, the in vitro (substrate: midazolam and nifedip-
ine) and in vivo (substrate: nifedipine) metabolic studies of CYP3A1/2 substrates were carried out. In in vitro 
studies, the maximum velocity (Vmax) of dehydronifedipine formation in rat liver microsomes (RLM) of dou-
ble KO rats was 0.20 ± 0.01 nmol/min/mg protein, a significant decrease (about 50%) of that in WT controls 
(0.40 ± 0.01 nmol/min/mg protein) (Fig. 6a,b). The Michaelis constant (Km) value of KO RLM was 9.97 ± 1.13 μ M, 
which was slightly decreased by 12% compared with that in WT RLM (11.37 ± 1.10 μ M) (Fig. 6c). Meanwhile, the 
intrinsic clearance (CLint) of nifedipine in the RLM of double KO rats significantly decreased by 43% compared 
with that in WT RLM (Fig. 6d). Moreover, the Vmax and CLint of midazolam in the RLM of double KO rats also 
significantly decreased by 75% and 70%, respectively, compared with those in WT RLM (Fig. 6f,h). In summary, 
the CYP3A1/2 activity of KO rats was significantly decreased in our metabolic studies of the CYP3A substrates 
nifedipine and midazolam in vitro.
To further explore the impaired function of CYP3A1/2 in Cyp3a1/2 double KO rats in vivo, a single dose of 
nifedipine (200 μ g/kg) was administered through the tail vein in both KO and WT rats. As shown in Table 2, 
the area under the time-plasma concentration curve (AUC) of nifedipine in double KO rats was increased by 
61% compared with that in WT rats. Furthermore, in KO rats the elimination half-time (t1/2) was significantly 
prolonged by 93%, together with a 25% increase in the mean residence time (MRT) and a 50% decrease in the 
Match Name Coordinate Spacer + PAM Number of mismatch off-target score
Cyp3a1 sgRNA CAAGAAACAGGGGATTCCTGG
Cyp3a1-off-1 Chr12: 12839905 to 12839886 AAGAAACAGGGaATTCCTGG 1 0.70
Cyp3a1-off-2 Chr12: 13740208 to 13740189 AAGAAACAaGGaATTCCTGG 2 0.56
Cyp3a1-off-3 Chr12: 17502003 to 17501985 AGAgACAGGGGATcCCTGG 2 0.50
Cyp3a1-off-4 Chr12: 43976656 to 43976638 AGAgACAGGGGATcCCaGG 3 0.50
Cyp3a1-off-5 Chr12: 16851108 to 16851124 AAACAGGGGATcCCgGG 2 0.50
Cyp3a1-off-6 Chr12: 41792250 to 41792265 AACAGGGGATTCCaGG 1 0.50
Cyp3a1-off-7 Chr12: 5140566 to 5140580 ACAGGGGATTCCaGG 1 0.50
Cyp3a1-off-8 Chr13: 50280364 to 50280382 AGAcACAGGGGATTCCTGG 1 0.50
Cyp3a2 sgRNA TAAGAAACAAGGAATTCCTGG
Cyp3a2-off-1 Chr12: 12747958 to 12747978 TAAGAAACtAGGAATTCCTGG 1 0.70
Cyp3a2-off-2 Chr12: 12839906 to 12839886 TAAGAAACAgGGAATTCCTGG 1 0.70
Cyp3a2-off-3 Chr12: 13172446 to 13172427 AAGAAACAgGGgATTCCTGG 2 0.63
Cyp3a2-off-4 Chr12: 52934974 to 52934956 AGAtACcAGGAATTCCaGG 3 0.56
Cyp3a2-off-5 Chr12: 40658157 to 40658141 AAAgAAGGAATTCCTGG 1 0.50
Table 1.  Details for potential off-target sites examined.
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clearance (CL), compared with these in WT rats. These data reflected that the function of CYP3A1/2 in KO rats 
was impaired in vivo. Therefore, the pharmacokinetic results of nifedipine in vivo were in agreement with the 
in vitro results, indicating that CYP3A1/2 was functionally inactive in the double KO rat line.
Compensatory expression of other CYP isoforms in Cyp3a1/2 KO rats. Since Cyp3a1/2 deletion 
may affect the expression of other CYP isoforms, the mRNA levels of the other main rat CYP enzymes were 
checked via quantitative real-time PCR. Compared with WT rats, no significant change was observed in the 
hepatic and small intestinal expression of CYP1A2, CYP2D1, CYP2D2, CYP2E1, and CYP3A9 (Fig. 7). In con-
trast, the hepatic mRNA expression of CYP2C11 and CYP3A18 in double KO rats was increased by nearly 290% 
and 300%, respectively, compared with WT controls (Fig. 7). Meanwhile, in small intestine of KO rats, the expres-
sion of CYP3A18 and CYP3A62 was up-regulated by 60% and 93%, respectively (Fig. 7).
Discussion
CYP3A as the most abundant human liver CYP enzyme is not only involved in the biotransformation of many 
endogenous substances, such as fatty acids, eicosanoid sterols, bile acids and vitamin D4, but also partici-
pates in the metabolism of over 75% of clinical drugs18. Traditionally, the roles of CYP3A in metabolism and 
metabolism-based toxicity have been investigated using specific antibodies or ‘selective’ chemical inhibitors, but 
in later studies most of these ‘specific’ modulators turned out to be nonspecific and even toxic under physiological 
conditions19,20. Therefore, a novel Cyp3a KO animal model is needed to study the functions of CYP3A in vivo. 
To our knowledge, the present work is the first time to successfully create a Cyp3a1/2 double KO rat model using 
CRISPR-Cas9 system.
Traditional gene targeting via embryonic stem cells to generate specific modified alleles is a potent tool to 
illustrate functions of genes in mice21. In rats, however, this genome manipulation method in stem cells does 
not work because of some technical difficulties10,22. In recent years, the emergences of engineered nucleases, 
Figure 3. Off-target analysis of CRISPR-Cas9 induced mutation in three (a) Cyp3a1 and (b) Cyp3a2 double KO 
rats. Eight OTSs for Cyp3a1 sgRNA and five OTSs for Cyp3a2 sgRNA were selected for T7E I enzyme cleavage. 
No mutations were found in PCR products, suggesting that CRISPR-Cas9 did not disrupt the off-target 
sequences tested in this study. Cyp3a1 off, OTS for Cyp3a1 sgRNA; KO, Cyp3a1 and Cyp3a2 double KO rat; T7E 
I− , before T7E I digestion; T7E I+ , after T7E I digestion; M, DNA molecular weight marker.
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Figure 4. Physiological phenotype of Cyp3a1/2 double KO rats. (a) Clinical chemistry and physiological 
analysis of Cyp3a1/2 double KO rat serum compared with WT rats. Serum samples were collected at nearly 8 
weeks and analyzed for HDL-CHOL, LDL-CHOL, T-CHOL, TRIG, AST, ALT, AST/ALT, AP, ALB, GLB, ALB/
GLB, TP, ID-BIL, D-BIL, T-BIL, GLUC, PEG2, 25-OH vitamin D, testosterone and bile acid. Organ coefficient 
of Cyp3a1/2 double KO rat (about 8 weeks) liver compared with WT rats. LW, liver weight; BW, body weight. 
The organ coefficient was defined as LW/BW ratio. Data were shown as Mean ± SEM of six rats. (b) HE staining 
of liver and small intestine slices from WT and Cyp3a1/2 double KO rats (n = 6). Scale bar = 100 μ m.
www.nature.com/scientificreports/
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such as ZFNs and TALENs, have been used for gene editing in rats. However, they are still limited by the time- 
and labor-consuming construction of engineered specific protein pairs for every target site10. More recently, a 
state-of-the-art engineered nuclease, the CRISPR-Cas9 system, has proved a simple method to manipulate genes 
in rats8,10,13. In particular, we have used the CRISPR-Cas9 tool to successfully knock out the Cyp2e1 gene from 
the rat12.
In rats, the high degree of nucleotide similarity between CYP3A1 and 3A2 presents a major challenge towards 
simultaneous disruption of these isozymes. However, compared with previous techniques such as ZFNs and 
TALENs, the CRISPR-Cas9 system displays distinct advantages in editing multiple genes simultaneously10,13. 
Therefore, we targeted the Cyp3a1 and Cyp3a2 genes simultaneously via the CRISPR-Cas9 system. In this study, 
the CRISPR-Cas9 tool showed great advantages again in successfully achieving precision gene targeting in the rat 
by co-microinjection of Cyp3a1 and Cyp3a2 sgRNA with Cas9 mRNA into zygotes.
The Cyp3a1/2 double KO rats were viable and fertile. At first, we thought simultaneous KO Cyp3a1/2 might 
show disruptive effects on rat physiology. However, our data indicated that Cyp3a1/2 double KO rats possessed 
equivalent levels of cholesterol, aminotransferase, glucose, bilirubin, PEG2, 25-hydroxy vitamin D, bile acid as 
well as serum proteins (Fig. 4). These results revealed that CYP3A may work as an important rather than exclusive 
contributor to the metabolism of endogenous substances, which is also in agreement with its role in the Cyp3a 
KO mouse model3. Recently, it has been reported that Cyp3a KO mice showed higher levels for bile acid and 
testosterone compared with WT mice23,24. In contrast, Cyp3a KO rats only presented higher level of testosterone 
than that of WT rats, thus suggesting different species possess different metabolic characterization. Moreover, 
some studies have reported that the deletion of one Cyp gene in mouse may lead to compensatory changes in 
other CYP metabolic enzymes25. Therefore, the mRNA levels of other main CYP isoforms were quantified in this 
Figure 5. mRNA and immunohistochemical detection of Cyp3a1 and Cyp3a2 in double KO and WT 
male rat liver and small intestine. (a) Hepatic mRNA of WT rats and KO rats was detected by using agarose 
gel electrophoresis. β-actin was set as the reference gene. (b) Liver and small intestine sections were used for 
immunohistochemical staining. Experiments were repeated three times independently.
www.nature.com/scientificreports/
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Figure 6. CYP3A-mediated metabolic activity in Cyp3a1/2 double KO and WT rats in vitro. (a) The 
saturation curve of nifedipine metabolism in liver microsomes from both double KO and WT rats. (b) The 
Vmax values of nifedipine metabolism in both double KO and WT male RLM. (c) The Km values of nifedipine 
metabolism in both double KO and WT male RLM. (d) The CLint values of nifedipine metabolism in both 
double KO and WT male RLM. (e) The saturation curve of midazolam metabolism in liver microsomes from 
both double KO and WT male rats. (f) The Vmax values of midazolam metabolism in both double KO and 
WT male RLM. (g) The Km values of midazolam metabolism in both double KO and WT male RLM. (h) The 
CLint values of midazolam metabolism in both double KO and WT male RLM. All data were expressed as 
mean ± SEM of six rats in each group, and ***p < 0.001 compared to WT rats.
www.nature.com/scientificreports/
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study. Our data exhibited there were no statistically significant changes in most CYP enzymes, apart from a com-
pensatory increase of Cyp2c11 (2.9-fold) and Cyp3a18 (3-fold) mRNA in liver, Cyp3a18 (1.63-fold) and Cyp3a62 
(1.93-fold) in small intestine (Fig. 7). The up-regulation of Cyp2c11, Cyp3a18 and Cyp3a62 may be owed to the 
ligand-activated transcription factor, which is known as the pregnane X receptor (PXR) or pregnane-activated 
receptor26,27. Our further study showed that the mRNA level of PXR was about 1.5-fold higher in KO rat liver 
compared with WT rats (data not shown). Due to the up-regulation of Cyp3a18 and 3a62 in KO rats, it would be 
better to delete all of CYP3A isoforms in the rat to completely eliminate the Cyp3a background28. In spite of these 
limitations, the Cyp3a1/2 KO rat model is still a novel and useful animal model to explore the physiological and 
pharmacological roles of CYP3A and to assess whether the absence of CYP3A could arouse compensatory metab-
olism by non-CYP enzymes or other CYP isoforms in rats. For example, in this study, there was discrepancy of 
midazolam between in vitro metabolic study using liver microsomes and in vivo pharmacokinetic study in WT 
rats. Therefore, it is difficult to decide whether midazolam has the compensatory metabolic pathways in vitro and 
in vivo. However, a CYP2C specific inhibitor or antibody may be effective to explore the compensatory effect of 
CYP2C in the metabolism of midazolam when Cyp3a1/2 KO rat model is used.
The Cyp3a1/2 double KO rat model can be used in vivo to study CYP3A-mediated drug metabolism and 
pharmacokinetics. In this study, nifedipine and midazolam as CYP3A substrates were used to detect the 
CYP3A-mediated catalytic activity in WT and double KO rats. RLM from double KO rats showed a decreased 
in vitro metabolic activity both on nifedipine and midazolam (Fig. 6), suggesting the loss of CYP3A. However, 
residual metabolites of nifedipine and midazolam were still formed by RLM from double KO rats, which may be 
ascribed to other hepatic CYP isoforms and/or the compensatory up-regulation of other CYP isoforms. For exam-
ple, previous studies have reported that midazolam is the probe substrate of CYP3A, but CYP2C also takes part in 
its metabolism25,29,30. In this study, we compared the pharmacokinetic profiles of midazolam between CYP3A1/2 
KO and WT rats. However, there was no obvious difference of the pharmacokinetics of midazolam between KO 
and WT rats. Therefore, we used nifedipine instead of midazolam in the in vivo pharmacokinetic studies. The 
results in vivo showed that the exposure of nifedipine (AUC value) in Cyp3a1/2 KO rats significantly increased 
by 61%, together with increases in the t1/2 (93%) and MRT (25%), compared with WT rats (Table 2). Our findings 
demonstrated that Cyp3a1/2 double KO rats were a sensitive animal model to investigate the CYP3A-mediated 
metabolic pathway of chemicals, especially in in vivo studies. Given that a discrepancy in CYP3A exists between 
rats and humans, a CYP3A humanized rat model should be further created to overcome the species differences.
In conclusion, the CRISPR-Cas9 method was described to successfully create the Cyp3a1/2 double KO rat 
model. The Cyp3a1/2 double KO rats were viable, fertile, and physiological normal. The Cyp3a1/2 double KO 
rats are a valuable animal model to investigate the roles of CYP3A in drug and chemical metabolism, toxicity and 
carcinogenicity in vivo.
Methods
Materials and chemicals. Oligos (60 bp, containing Cyp3a1 or Cyp3a2 knock out target-sites) and all prim-
ers for PCR were synthesized from Biosune Biotechnology Co. LTD (Shanghai, China). In vitro Transcription 
T7 Kit, SYBR Premix Ex Taq, Prime Script RT Reagent Kit and TA cloning kit were bought from Takara (Dalian, 
China). mMessage mMachine SP6 kit were purchased from Thermo Scientific (Massachusetts, USA). The second-
ary antibody conjugated to HRP-labeled polymers was bought from Mrbiotech (Shanghai, China). Midazolam 
was purchased from Enhua (Nanchang, China). Mebendazole was purchased from Aladdin (Shanghai, China).
Animals. Male and female SD rats (8-week old) were purchased from National Rodent Laboratory Animal 
Resources, Shanghai Branch of China. The animals were kept in a specific pathogen-free facility with access to 
rodent chow cubes and sterile water, with 12 h light-dark cycles. All the methods performed in animals were car-
ried out in accordance with the National Institutes of Health standards established in the ‘Guidelines for the Care 
and Use of Experimental Animals’. All experimental protocols in animals were approved by the Ethics Committee 
on Animal Experimentation of East China Normal University (Shanghai, China).
Cyp3a1 and Cyp3a2 KO target site selection. The sequence fragments of Cyp3a1 and Cyp3a2 were 
submitted to an online design tool (CRISPR Design Tool, http://tools.genome-engineering.org) to generate the 
Pharmacokinetic parameter WT KO
t1/2 (min) 35.52 ± 8.29 68.42 ± 9.23***
C0 (ng/mL) 926.52 ± 142.87 870.74 ± 204.87
AUC0–120 min (min·ng/mL) 26979.23 ± 1522.03 43338.98 ± 7259.09**
AUC0−∞ (min*ng/mL) 30118.55 ± 2436.55 61124.74 ± 10417.95***
Vd (mL/kg) 341.11 ± 83.37 332.07 ± 80.81
CL (mL/min/kg) 6.67 ± 0.51 3.36 ± 0.68***
MRT (min) 38.06 ± 5.41 47.74 ± 2.21**
Table 2. Pharmacokinetic parameters of nifedipine in double KO and WT rats. t1/2, half life; C0, initial 
plasma concentration; AUC0–120min, area under the plasma concentration-time curve during 0–120 min; 
AUC0–∞, area under the plasma concentration-time curve during 0− ∞ ; Vd, apparent volume of distribution; 
CL, clearance; MRT, mean residence time. All data were expressed as mean ± SEM (n = 5). **p < 0.01 and 
***p < 0.001 compared with WT rats.
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potential target sites. Cyp3a1 and Cyp3a2 in rats contain 13 and 10 exons, respectively. To silence the Cyp3a1 and 
Cyp3a2 gene as completely as possible, target-sites were selected just downstream to the initiation codon, ATG, 
and followed by a protospacer adjacent motif (PAM) site (5′ -NGG-3′ ) in the 3′ end.
DNA constructs and in vitro transcription. The sgRNA expression vector and Cas9-encoding plasmid 
were constructed according to our previous work14. Then oligos (60 bp, containing Cyp3a1 or Cyp3a2 knock 
out target-sites) were cloned into the pGS3-T7-gRNA vector through overlapping PCR for the transcription of 
sgRNA in vitro. Cyp3a1 and Cyp3a2 sgRNA were then transcribed with the in vitro T7 Transcription Kit respec-
tively. RNA was purified through phenol/chloroform extraction and dissolved in diethylpyrocarbonate-treated 
or RNase-free water.
Figure 7. The mRNA expression levels of the other main CYP isoforms in Cyp3a1/2 double KO and WT 
rats. The expression of other isoforms was measured in rat liver (a) and small intestine (b). β-actin was used 
as the reference gene and was stably expressed in both WT and KO rat liver and small intestine. All data were 
expressed as mean ± SEM (n = 5), and **p < 0.05, ***p < 0.001 compared to WT controls.
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For the transcription of Cas9 mRNA, the linearized Cas9 expression vectors were purified through phe-
nol/chloroform extraction and ethanol precipitation followed by the transcription of Cas9 mRNA using the 
mMessage mMachine SP6 kit. The mRNA was recovered by Lithium chloride precipitation and resuspended 
in Nuclease-free water. Purified Cyp3a1 and Cyp3a2 sgRNA and Cas9 mRNA products were confirmed by 
electrophoresis.
Co-microinjection of sgRNA and Cas9 mRNA into zygotes. Rat preparation and microinjection were 
performed as described with modifications14. Briefly, the TE buffer containing 25 ng/μ L of Cyp3a1 sgRNA, 25 ng/μ L 
of Cyp3a2 sgRNA and 50 ng/μ L of Cas9 mRNA were co-injected into the cytoplasm of one-cell stage embryos. 
The microinjected zygotes were transferred into pseudopregnant female rats immediately after injection or after 
overnight culture in embryo culture medium.
Genotyping of founders and progenies. For the F0 generation, newborn rats were genotyped 7 to 10 
days after birth. Purified genomic DNA was amplified using the primers listed in Table 3 (No. 1, 2). T7E I assay 
was used for a preliminary screening for the potential mutations in founders on target-sites. To identify the mod-
ification details in founders, containing potential mutations, PCR products from each founder was cloned into 
pMD-18T vectors for sequencing with the universal primers of the vector. For the F1 and F2 generations, the gen-
otype was identified by sequencing the PCR products directly. Sequence data was analyzed through DNAMAN 
(LynnonBiosoft, CA, USA) to identify the exact genotype (WT, heterozygote and double KO rats) of founders. 
Specificity of all primer pairs (No. 1 to No. 26) used in our research was checked using agarose gel electrophoresis, 
indicating a single and specific band for each pair of primer under our experimental conditions.
Off-target site validation. The target sites of Cyp3a1 and Cyp3a2 were submitted to Cas9 online designer 
(http://cas9.wicp.net/). The degree of off-target was measured by an ‘off-target score’, which ranges from 1 to 0. 
‘1’ means a high probability of off target and ‘0’ a low probability of off target events. OTS with a score ≥ 0.5 were 
selected for PCR analysis. The PCR product of each off-target site was subjected to T7E I digestion and then 
resolved on a 1.5% agarose gel to analyze the off-target effects.
Hematoxylin and eosin (HE) staining of rat liver and small intestine slices. About 8-week old rats 
were sacrificed through cervical dislocation. Livers and intestines were freshly excised and then fixed in 4% para-
formaldehyde at 4 °C for more than 12 h. The fixed intestines were dehydrated in 50%, 75%, 85%, 95%, and 100% 
ethyl alcohol for one hour for each and then immersed in ethyl alcohol and xylene mixture (v/v = 1:1) for 30 min, 
followed by two 15 min intervals in xylene, followed by paraffin embedding. The fixed livers similarly treated, 
except dehydration for 30 min per step and 15 minute immersion in the ethanol:xylene mixture. Sections (4 μ m) 
were then deparaffinization for hematoxylin and eosin (H&E) according to normal procedures.
Clinical-chemical and hematological analysis of Cyp3a1 and Cyp3a2 double KO and WT rats. 
To further characterize the potential effects of Cyp3a1 and Cyp3a2 KO on the normal rat physiology, the serum 
samples were collected for clinical-chemical and hematological analysis. The serum samples were sent for analysis 
by ADICON Clinical Laboratories (Shanghai, China). For the analysis of PGE2, a rat PEG2 ELISA kit was bought 
from Shanghai MLBIO Biotechnology Co.Ltd (Shanghai, China).
Cyp3a1 and Cyp3a2 mRNA expression in rat liver. About 8-week old rats were sacrificed through cer-
vical dislocation method. Livers mRNA was extracted through Trizol and the RNA was reverse-transcribed into 
cDNA using the Takara RR036A RT kit. For the detection of cyp3a1 and cyp3a2 mRNA expression, selective 
primers (spanning different exons) were designed and synthesized which were listed in Table 3 (No. 24, 25). 
β-actin (Primer listed in Table 3, No. 26) was used as the internal reference.
Immunohistochemical analysis. Immunohistochemistry on double KO and WT rat liver and small intes-
tine was conducted with a commercial rabbit anti-human CYP3A4 polyclonal antibody (1:100, ab3572, Abcam), 
which cross-reacts with rat CYP3A, and a secondary antibody conjugated to HRP-labeled polymers (MR-SPR120, 
Mrbiotech).
Quantitative reverse transcriptase PCR. SYBR-PCR was performed using a Stratagene Mx3005P with 
SYBR Premix Ex Taq. The relative mRNA expression was measured by 2−ΔΔCt 31. The primers (spanning different 
exons) used for quantitative reverse transcription-PCR were listed in Table 3 (No. 16–23, 26). Dissociation curves 
of primer pairs for quantitative reverse transcriptase-PCR were monitored, showing a high specificity for our 
primer pairs.
Preparation of RLMs. The protocol of RLM preparation was modified from our previous studies32,33. The 
liver was separated, rinsed with ice-cold normal saline and homogenized in a 0.05 M Tris/KCl buffer (pH 7.4). The 
homogenate was centrifuged at 10,500 g at 4 °C for 30 min. The supernatant was then centrifuged at 105,000 g at 
4 °C for 60 min. The precipitate was resuspended and re-centrifuged at 105,000 g at 4 °C. The pellet was reconsti-
tuted with the 0.05 M Tris/KCl buffer (pH 7.4) and stored in − 80 °C for use.
The CLint of nifedipine and midazolam in Cyp3a1 and Cyp3a2 double KO and WT RLM. For the 
research of CYP3A1 and CYP3A2 enzymes activity in vitro, nifedipine and midazolam were chosen as specific 
substrates and dehydronifedipine and 1′-hydroxymidazolam were monitored, respectively34–37. The incubation 
mixture consisted of an NADPH (β -Nicotinamide adenine dinucleotide phosphate hydrate)-regenerating system, 
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nifedipine (2 μ M to 100 μ M) or midazolam (10 μ M to 100 μ M) and 0.5 mg/mL (for nifedipine) or 1 mg/mL (for 
midazolam) of RLM in 0.05 M Tris-HCl buffer (pH 7.4). The supernatant of the incubation mixture was trans-
ferred to the autosampler vial after a protein precipitation process for LC-MS/MS analysis. Km and Vmax were 
analyzed according to the standard Michaelis-Menten equation by GraphPad Prism 5. The CLint was defined as 
the Vmax/Km ratio.
Pharmacokinetics of nifedipine in Cyp3a1 and Cyp3a2 double KO and WT rats. Nifedipine (200 μ g/kg) 
was administered through the tail vein for all WT and KO rats and blood samples were collected into heparinized 
centrifuge tubes at 2, 5, 10, 20, 30, 45, 60, 90, and 120 min by orbital bleeding with capillary tubes. Blood samples 
were centrifuged as soon as possible at 5,500 g for 15 min, and the plasma was transferred into new tubes and 
frozen at 0 °C for further analysis.
LC-MS/MS analysis of 1’-hydroxymidazolam, nifedipine and dehydronifedipine. For the 
LC-MS/MS analysis, a 1290 HPLC-6460 triple quadrapole mass spectrometer coupled with an ESI ion source 
(Agilent Technologies, USA) was employed. For 1′ -hydroxymidazolam detection, a Zorbax Eclipse C18 column 
(2.1*50 mm, 1.8 μ m; Agilent Technologies, USA) was used with a mobile phase system of water (A)-acetonitrile 
(B). The ion transitions of 342.0 → 324.0 and 285.0 → 193.1 for 1′ -hydroxymidazolam and diazepam (IS) were 
monitored in positive ESI mode, respectively.
For the detection of nifedipine in rat plasma, the mobile phase consisted of water (A) and acetonitrile (B). The 
detection of the ions was performed in the multiple reactions monitoring (MRM) mode, monitoring the transi-
tion of m/z 347.1 to the m/z 315.1 product ion for nifedipine, and m/z 296.1 precursor to m/z 264.1 product ion 
for mebendazole (IS). The liquid–liquid extraction method was used to isolate nifendipine and IS from plasma.
For the detection of dehydronifedipine, a Phenomenex Kinetex XB-C18 column (100 × 3.00 mm, 2.6 μ m) 
was used. The gradient elution was conducted with a mobile phase system of water (A)-acetonitrile (B). The ion 
transitions of 345.3.0 to 284.1 and 296.1.0 to 264.1 for dehydronifedipine and mebendazole (IS) were monitored, 
respectively.
Data analysis and statistics. All data were presented as mean ± SEM. Statistical analysis between dif-
ferent groups was performed using two-tailed t-test and p-values less than 0.05 were considered to indicate 
statistical significance. The enzyme kinetic data of nifedipine and midazolam metabolism in RLM was fitted 
according to the typical Michaelis-Menten equation with GraphPad Prism 5.0 (GraphPad Software, CA, USA). 
No. Primer Name Primer Sequence (5′ → 3′) No. Primer Name Primer Sequence (5′ → 3′)
1
Cyp3a1-genotyping-S TAGCATTACCCTGGCACCT
14
Cyp3a2-off-4-S GCGGGTGGAAGAAGAGTG
Cyp3a1-genotyping-A GCCAAAGCCTGGATACACTC Cyp3a2-off-4-A TTGTGCAGAGCCAGATGC
2
Cyp3a2-genotyping-S TAGAGGGAGAACACCGAGGAG
15
Cyp3a2-off-5-S TATCAACTACTGTTTCCCAATG
Cyp3a2-genotyping-A GGGTCCGATGTCTTAGGGTT Cyp3a2-off-5-A TGTAACTTGCGTGTAGACTTT
3
Cyp3a1-off-1-S AGACCCAAGGGACTCAAA
16
Cyp1a2-qPCR-S ATGTCACCTCAGGGAATG
Cyp3a1-off-1-A AACATCCACCAGCAGTTT Cyp1a2-qPCR-A CACCGTTGTCTTTGTAGTTC
4
Cyp3a1-off-2-S CCAGGGACTCACAAACAT
17
Cyp2c11-qPCR-S AAAGCACAATCCGCAGTC
Cyp3a1-off-2-A GAACCCAAACATCCACAT Cyp2c11-qPCR-A CATCCGTGTAGGGCATCT
5
Cyp3a1-off-3-S TGGAAGCCAGAGGTTGAT
18
Cyp2d1-qPCR-S ATGATTCTATACCCGGATGTG
Cyp3a1-off-3-A TTCCCACAGTCTGCCATT Cyp2d1-qPCR-A ACGGACGACAGGTTGATG
6
Cyp3a1-off-4-S TGTGTCTATGTTGTGTATATCTGGG
19
Cyp2d2-qPCR-S GCAGGTGGACTTTGAGAAC
Cyp3a1-off-4-A CGGCAGGAAGAGATAAATGACAGAT Cyp2d2-qPCR-A GATTATAGATGGGCAGTAGGG
7
Cyp3a1-off-5-S GTGAGCTGCCCATGTTAA
20
Cyp2e1-qPCR-S GATCTATAACAGTTGGAACCTGCCCC
Cyp3a1-off-5-A ATCCCATCTGATCTGTCG Cyp2e1-qPCR-A CAGGACCACGATGCGCCTTGAGCCA
8
Cyp3a1-off-6-S ACACTGCCCTAACGCTCAT
21
Cyp3a9-qPCR-S CTGTGGGTTGTTAAGGGAA
Cyp3a1-off-6-A CACGCCCTCACCTAATCT Cyp3a9-qPCR-A TGAGGCAGGGATCGGAGGA
9
Cyp3a1-off-7-S GAGGGCAGTTTCAGGTAT
22
Cyp3a18-qPCR-S ACCCAAACCTGTGCCTTTA
Cyp3a1-off-7-A TCTTTGGAGGGTCTTTCT Cyp3a18-qPCR-A CACATGCCATCACCGTAG
10
Cyp3a1-off-8-S CAATGGGATTTGTGGAGG
23
Cyp3a62-qPCR-S TGCTCCTGTATCTGTATGG
Cyp3a1-off-8-A CACCCTTTTCTCACAGCTCCT Cyp3a62-qPCR-A ATGGCAGTGTCTATCAAAC
11
Cyp3a2-off-1-S CGTCGGGTTTGATTCTTG
24
Cyp3a1-cDNA-S GCTGAATTACTATATGGGTT
Cyp3a2-off-1-A CAGCACTTGGGAGACAGA Cyp3a1-cDNA-A TCATGATCCAGTTATGATTT
12
Cyp3a2-off-2-S AGACCCAAGGGACTCAAA
25
Cyp3a2-cDNA-S TAGGCACTGTGCTGAATTAC
Cyp3a2-off-2-A GGAGGAGCAGCCAATCGT Cyp3a2-cDNA-A TCAGGCTCCATTTATGAC
13
Cyp3a2-off-3-S TGATGTCTCAGGGTTTCC
26
β-actin-S GTACGCCAACACAGTGCTG
Cyp3a2-off-3-A TCTAGTTATCCCTAGTTCCA β-actin-A CGTCATACTCCTGCTTGCTG
Table 3.  Primer pairs used in the research.
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Pharmacokinetic parameters were calculated by WinNonlin software version 5.2.1 (Pharsight Corporation, 
Mountain View, USA) based on non-compartmental analysis.
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